Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio is viewed favorably because its lead candidate buntanetap is advancing through a Phase 3 early Alzheimer’s disease program with 6-month and 18-month components, and enrollment has completed with 850 patients, reducing execution risk ahead of key readouts expected in 1Q27 and 1Q28. The company also strengthened its balance sheet by extending runway through 2Q27 while reporting 2Q26 operating expenses of $14.4mn, below the $18.3mn estimate, which supports continued development without immediate funding pressure. Given the huge unmet need in Alzheimer’s disease, buntanetap’s intriguing mechanism of action, and additional pipeline assets with positive clinical signals and FDA alignment, the company appears significantly undervalued on a fundamental basis.

Annovis Bio is a high-risk clinical-stage company whose negative outlook is driven by a very modest cash runway and the likely need for financing that could dilute shareholders. Its pipeline is concentrated in difficult-to-treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, where late-stage failure from weak efficacy, safety issues, or lack of FDA acceptance remains a major threat, even though early Alzheimer’s data showed statistical significance on Adas-Cog in the biomarker-positive mild AD population on 4/29/24. Although the FDA accepted the 6/18-month protocol on 1/7/25 and the trial was initiated on 2/5/25, enrollment completion is only expected in Spring-26, leaving substantial execution, regulatory, and commercialization risk.